The 20 Best Prostate Cancer Doctors Near Me in Rosedale, MD

Dr. Michael A. Carducci is the AEGON Professor in Prostate Cancer Research at the Johns Hopkins University School of Medicine. He serves as the Vice Chair of Solid Tumor Oncology in the Department of Oncology. Dr. Carducci has an expertise in various types of cancer including prostate, kidney, and testicular. He also has an expertise in clinical trials, pain and palliative care for oncology, urological oncology, urology and medical oncology. A graduate of Georgetown University, Dr. Carducci received his medical degree with high distinction from Wayne State University School of Medicine. He completed an internal medicine internship, residency and chief residency at the University of Colorado Health Sciences Center. He went on to complete medical oncology and research fellowships at the Johns Hopkins Oncology Center at Johns Hopkins Hospital. He was promoted to Professor of Oncology and Urology in 2008 and installed into the inaugural AEGON Professorship in Prostate Cancer Research in 2009. He served as Co-Director of the GU Oncology program until 2013. In 2013, he assumed the leadership role of Associate Director for Clinical Research until being named Vice-Chair of Solid Tumor Oncology in 2024. A fellow of the American College of Physicians and a fellow of the American Society of Clinical Oncology, Dr. Carducci has received peer-reviewed funding for his clinical research from the National Cancer Institute, Department of Defense, and the Prostate Cancer Foundation. Mentorship of students, fellows, and junior faculty has been another focus of Dr. Carducci’s career in medicine, receiving numerous teaching awards. Dr. Carducci received the Michaele Christian Award and Lectureship for Oncology Drug Development at the National Cancer Institute in 2011. He chaired the Genitourinary Oncology Committee of ECOG-ACRIN from 2011-2024. In this role, he served on the GU Steering Committee for the NCI. Dr. Carducci is a member of the Investigational Drug Steering Committee for the NCI, and chaired that Committee for four years. He served as Associate Editor for GU Cancers for the Journal of Clinical Oncology from 2013-2024. Overall, his clinical research focus is on the development and evaluation of new therapies for urologic cancers. Incorporation of pharmacodynamics, novel biomarkers, and targeted imaging has been key elements of many of the trials led by Dr. Carducci. To complete these studies, Dr. Carducci facilitates and brings together a multidisciplinary team from urologists, radiation oncologists, pathologists, biostatisticians, and medical oncologists. Other areas of interest include palliative and end of life care, survivorship, and use of patient reported outcomes in clinical research and care. This provider is registered with the Florida Department of Health to perform telehealth services for patients in Florida. Dr. Carducci is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Chromophobe Renal Cell Carcinoma, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy.

Dr. Kenneth Pienta is the Donald S. Coffey Professor of Urology and a professor of oncology at the Johns Hopkins School of Medicine. He also holds an appointment in the department of pharmacology and molecular sciences. He is an internationally recognized leader in prostate cancer research and translational science. Dr. Pienta serves as the director of research for the Brady Urological Institute and co-leader of the Kimmel Cancer Center's Prostate Cancer Program. Dr. Pienta has a proven, peer-reviewed track record in organizing and administering a translational research program that successfully incorporates bench research, agent development and clinical application. He has international expertise in the development of novel chemotherapeutic programs for prostate cancer and has championed the concept that translational research is often best accomplished by multi-disciplinary teams of scientists and clinicians. Under his direction, the success of these endeavors led to the receipt of the first annual American Association for Cancer Research Team Science Award in 2007. Dr. Pienta received his B.A. in human biology from the Johns Hopkins University. He earned his M.D. from the Johns Hopkins School of Medicine. He completed his residency at the University of Chicago Hospitals and Clinics and performed a fellowship in oncology at The Johns Hopkins Hospital. Prior to joining Johns Hopkins, Dr. Pienta was the associate vice president for research, health sciences for the University of the Michigan from 2012 to 2013 and director of precision medicine for the Michigan Center for Translational Pathology from 2008 to 2013. He joined the Johns Hopkins faculty in 2013. Dr. Pienta's research interests include the ecology of cancer, tumor microenvironment, metastasis, biomarker development and novel therapeutic development. Dr. Pienta is a two-time American Cancer Society Clinical Research Professor Award recipient. He holds several patents, has authored more than 350 peer-reviewed articles and has been the principle investigator on numerous local and national clinical trials. Dr. Pienta is currently actively developing clinical trials and treating patients with newly diagnosed high risk and metastatic prostate cancer. Dr. Pienta is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Bone Tumor, Familial Prostate Cancer, Prostatectomy, and Orchiectomy.

Dr. Christian Pavlovich is Bernard L. Schwartz Distinguished Professor in Urologic Oncology at the Johns Hopkins University School of Medicine and Director of the Prostate Cancer Active Surveillance Program at the Brady Urological Institute. Dr. Pavlovich treats cancer with an emphasis on minimizing morbidity and maximizing quality of life while offering patients the latest treatment options and techniques. His clinical focus is on prostate and kidney cancer, and on clinical trials regarding detection, surveillance, and immunotherapy. With more than 20 years of experience with minimally-invasive surgery for the treatment of urologic cancers, he is expert in robotic surgery and was named one of the top prostate cancer surgeons in the United States by Newsweek in 2024. In addition, he offers patients modern diagnostic biopsy techniques, and for prostate cancer patients active surveillance and ablative options including cryotherapy and TULSA. Dr. Pavlovich grew up in Washington DC, went to Harvard University, and then earned his medical degree at the University of California, San Francisco (UCSF) School of Medicine. He then completed a urology residency at New York Hospital-Cornell Medical Center and a National Cancer Institute SUO fellowship in urologic oncology before joining the Hopkins faculty in 2001. Dr. Pavlovich has published over 150 peer-reviewed articles, is Associate Editor of The Prostate and is on the Editorial Board of the British Journal of Urology International. He was the inaugural Director of the Brady Urological Institute’s SUO Urologic Oncology Fellowship (2014 -2024) and is the recipient of three “best teaching/research mentor” awards from the Urology residents at Johns Hopkins. Dr. Pavlovich speaks English, French, Spanish, German, and Serbo-Croatian. He enjoys spending time with his wife and children, following their pursuits, and skiing, diving, running, wildlife, and the great outdoors. Dr. Pavlovich is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Prostatectomy, and Nephrectomy.

Dr. Misop Han is David Hall McConnell Professor of Urology and Oncology at the Johns Hopkins School of Medicine. Dr. Han is a urologist whose main clinical focus is in urological oncology with a special emphasis on prostate and kidney cancers. He specializes in robotic nerve-sparing prostatectomy and robotic nephrectomy. Dr. Han received his undergraduate and medical degrees at Johns Hopkins. After an internship in surgery and residency in urology, also at Johns Hopkins, he worked as faculty at Northwestern University and Hospital in Chicago, Illinois. In 2006, he joined the Johns Hopkins faculty. His research interests include the outcome of radical prostatectomy, medical robotics and prediction modeling (what happens to men following surgery for prostate cancer). He has published extensively in these subjects and has received international and national recognition for his research. He is actively involved in several clinical research projects with the database of more than 20,000 men who received surgery for prostate cancer at The Johns Hopkins Hospital. He is a member of the American Urological Association and the American Medical Association. Dr. Han is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Ureterocele, Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Dr. Samuel Denmeade is the R. Dale Hughes Professor of Oncology and Urology at the Johns Hopkins University School of Medicine and Director of the Genitourinary Oncology Division for the Johns Hopkins Kimmel Cancer Center. He also has appointments in the Department of Pharmacology and Molecular Sciences and Department of Biomolecular Engineering. His areas of clinical expertise include bladder cancer, kidney cancer, prostate cancer and testicular cancer. Dr. Denmeade earned his M.D. from the Columbia College of Physicians and Surgeons of Columbia University. He completed his residency at the University of Chicago. He performed a fellowship in oncology at The Johns Hopkins Hospital and a fellowship in medical oncology at the Johns Hopkins University School of Medicine. His research interests include prostate cancer, bipolar androgen therapy, clinical trials and targeted drug development. Dr. Denmeade has published over 200 papers in the area of prostate cancer research. He has received extensive funding from the NIH, the Department of Defense Prostate Cancer Research Fund and the Prostate Cancer Foundation. He is the Editor-in-Chief of the medical journal The Prostate. Dr. Denmeade is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), Hormone Replacement Therapy (HRT), and Prostatectomy.

Mario Eisenberger is an Oncologist in Baltimore, Maryland. Dr. Eisenberger is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Chromophobe Renal Cell Carcinoma, Hormone Replacement Therapy (HRT), and Prostatectomy.

Herbert Carter is a Urologist in Baltimore, Maryland. Dr. Carter is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Hydrocele, Prostatectomy, and Vasectomy.

Arvin K. George, MD, is a urologic surgeon specializing in the diagnosis and management of genitourinary cancers, with particular sub-specialization in kidney and prostate cancers. His clinical interests and expertise are in image-guided therapeutics, and minimally-invasive ablative/surgical techniques for prostate and kidney cancer. These include laparoscopic and robotic surgery, in addition to cryoablation, high-intensity focused ultrasound ablation, nanoparticle directed laser ablation, laser interstitial thermal therapy, and bipolar radiofrequency ablation. Dr. George obtained his medical degree from the Royal College of Surgeons in Ireland, followed by a urology residency at the Smith Institute for Urology, Hofstra North Shore-LIJ School of Medicine. He remained to complete his endourology/minimally-invasive and robotic surgery fellowship in New York gaining additional subspecialty expertise in robotic, laparoscopic, and percutaneous surgery. Subsequently, he completed a urologic oncology fellowship at the National Cancer Institute, National Institutes of Health. He then joined the clinical facility at the University of Michigan, Ann Arbor, where he directed the Prostate Cancer Programs from 2019 through 2023. Dr. George participates extensively in the discovery of urologic science and evaluation of urologic care and has co-authored over 80 peer reviewed publications. Additionally, he has authored 11 chapters in medical education books. Dr. George sees patients in clinic throughout the Baltimore region and also is available for virtual appointments for patients in Maryland, Washington D.C., New York and Michigan. Dr. George is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Renal Cell Carcinoma (RCC), Familial Prostate Cancer, Prostatectomy, and Nephrectomy.

Dr. Mohamad Allaf is Professor of Urology and Oncology, as well as Director of the Department of Urology and the Brady Urological Institute and Urologist-in-Chief of the Johns Hopkins Hospital. Dr. Allaf is a world renowned surgeon-scientist having performed more than 2,000 robotic procedures and published over 250 peer reviewed research papers in the field's best journals. As one of the busiest robotic radical prostatectomy surgeons in the world, he aims to achieve the best outcomes for his patients. Having trained with Dr. Patrick Walsh, Dr. Allaf has used Dr. Walsh's method of radical prostatectomy as the basis for his own anatomic method to this complex operation. Dr. Allaf is also amongst the leaders in kidney cancer surgery, having served on the American Urological Association Guideline Committee for Kidney Cancer. He led a team who performed the rigorous analysis to help inform the most recent guidelines that was funded by the Agency for Healthcare Research and Quality (AHRQ). He is best known for his ability to save the kidney and remove the tumor in patients with kidney tumors. Dr. Allaf runs a research endeavor aiming to decrease the morbidity associated with the treatment of cancer, and he has mentored numerous leaders in academic urology. He is actively involved in fund raising for research and education, and believes in expanding our base of support in order to advance our important mission. Dr. Allaf is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Renal Cell Carcinoma (RCC), Renal Oncocytoma, Prostate Cancer, Nephrectomy, and Prostatectomy.

Mohummad Siddiqui is a Urologist in Baltimore, Maryland. Dr. Siddiqui is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Muscle Invasive Bladder Cancer, Bladder Cancer, Vasectomy, and Nephrectomy.

Phuoc Tran is a Radiation Oncologist in Baltimore, Maryland. Dr. Tran is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Lung Cancer, Prostatectomy, and Pancreaticoduodenectomy.

Benjamin Lowentritt is a Urologist in Towson, Maryland. Dr. Lowentritt is rated as an Elite provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Familial Wilms Tumor 2, Ureteroscopy, and Nephrectomy.

Dr. Civelek is a professor in the Johns Hopkins Medicine Department of Radiology and Radiological Science. He serves as the director of the Nuclear Medicine Residency Program. Dr. Civelek earned his medical degree at Istanbul University, Istanbul School of Medicine, and completed his residency at Hacettepe University Medical Center, Ankara. He received a scholarship from the International Atomic Energy Agency when he completed his nuclear medicine residency and fellowship at Johns Hopkins in the Division of Nuclear Medicine. After his period as a postdoctoral fellow, he joined Johns Hopkins Medicine as full-time faculty until 2003. In his early years at Johns Hopkins, Dr. Civelek assisted the clinical and research programs. He later served as director of nuclear cardiology and clinical director, the director of Nuclear Medicine Residency Program, as well as medical director of the Nuclear Medicine Technologist Program. Prior to his return to Johns Hopkins, Dr. Civelek was a professor and director of nuclear medicine and PET at the University of Louisville and a professor and director of nuclear medicine at the Saint Louis University Hospital. Dr. Civelek spent two years in the body MRI and MRI-PET section, Department of Radiology and Imaging Sciences, at National Institutes of Health Clinical Center before serving as the deputy chief in their nuclear medicine section. He is a fellow of the American College of Nuclear Medicine and The American College of Angiology, and is a fellow and founding member of the American Society of Nuclear Cardiology. Dr. Civelek has trained numerous American and international physicians in nuclear medicine, including nuclear cardiology and nuclear oncology. He has a worldwide reputation in nuclear medicine and lectures at medical centers in the U.S. and internationally on nuclear medicine, including nuclear cardiology and nuclear oncology/PET-CT and PET-MRI. Dr. Civelek is committed to the continued progress of nuclear medicine, cardiology and oncology and the development of new tumor-targeting radiopharmaceuticals for imaging and therapy. He supports high quality clinical trials and patient care and safety. To date, Dr. Civelek has published more than 210 peer-reviewed manuscripts and abstracts, and he has participated in and fostered many nuclear oncology research projects. He has served on the editorial boards of several journals. He is a reviewer for multiple scientific journals, including the Journal of Nuclear Medicine, American Journal of Radiology, and Journal of Urology. Dr. Civelek is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Neuroendocrine Tumor, Prostate Cancer, Lung Cancer, and Familial Prostate Cancer.

"Dr. Patrick C. Walsh is a professor of urology at the Johns Hopkins School of Medicine. He is recognized internationally as a pioneer in the diagnosis and treatment of prostate cancer. Dr. Walsh is best known for his pioneering work in the development of ""the anatomic approach to radical prostatectomy,"" which involves nerve-sparing techniques that have reduced the probability of impotence and incontinence, and for his 30 years as director of the Brady Urological Institute. He has also made major contributions to the basic understanding of benign and malignant neoplasms of the prostate. Along with co-workers, he was the first to describe the 5 alpha-reductase enzyme deficiency, to develop an experimental technique for the induction of benign prostatic hyperplasia, to demonstrate the influence of reversible androgen deprivation on BPH, and to characterize hereditary prostatic cancer. Dr. Walsh received his undergraduate and medical training at Case Western Reserve University. After an internship and junior residency in surgery at the Peter Bent Brigham Hospital in Boston, he conducted an assistant residency in pediatric surgery at The Children''s Hospital Medical Center in Boston, and a residency in urology as well as a fellowship in endocrinology at the University of California Los Angeles, School of Medicine. He joined the faculty of Johns Hopkins in 1974. In 2004 he was named University Distinguished Service Professor of Urology. Dr. Walsh has received dozens of national and international awards and honors. He has authored or co-authored more than 600 articles and three books, including a best-seller for lay people titled The Prostate: A Guide for Men and the Women Who Love Them. For 25 years he was the editor-in-chief of Campbell''s Textbook of Urology, which has been renamed in his honor. He is on the editorial board of the New England Journal of Medicine, is a member of numerous international professional organizations and has served as the president of both the American Association of Genitourinary Surgeons and the Clinical Society of Genitourinary Surgeons.". Dr. Walsh is rated as an Advanced provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Familial Prostate Cancer and Prostate Cancer.

Theodore DeWeese is The Frances Watt Baker, M.D., and Lenox D. Baker Jr., M.D. Dean of the Medical Faculty and CEO, Johns Hopkins Medicine. Dr. DeWeese is professor of oncology and urology at the Johns Hopkins University School of Medicine. His areas of clinical expertise include prostate cancer, radiation oncology and urological oncology. He and his colleagues focus their research on developing new ways to enhance radiation-induced killing of prostate cancer cells. This includes development of novel, prostate cancer-targeted RNA molecules as well as new ways to modulate androgen receptor signaling. He and his colleagues also developed the first adenoviral gene therapy trial for prostate cancer, using a common cold virus to target cancer cells while leaving normal cells unharmed. Dr. DeWeese earned his M.D. from the University of Colorado Health Sciences Center. He completed his residency at The Johns Hopkins Hospital, serving as chief resident, and performed a laboratory research fellowship at the Johns Hopkins Oncology Center and the James Buchanan Brady Urological Institute. Dr. DeWeese's research interests include prostate cancer, DNA damage, and radiation sensitization. Dr. DeWeese has served on numerous committees and boards including as President and Chair of the Board for the American Society for Radiation Oncology. He also serves on committees for the American Association for Cancer Research and was appointed by the National Academy of Sciences as a scientific counselor for the Radiation Effects Research Foundation in Hiroshima, Japan. He has received numerous awards and honors, including several teaching awards from Johns Hopkins. Make A Gift. Dr. Deweese is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Bone Tumor, Prostatectomy, and Orchiectomy.

Dr. Ana Kiess's clinical focus is on the treatment of prostate cancer and head and neck cancers with external beam radiotherapy and radiopharmaceutical therapies. Her research concentrates on the integration of new radiopharmaceutical therapies and dosimetry techniques into the clinic. Dr. Kiess received her bachelors of science degree in chemical engineering from the University of Virginia, after which she obtained a doctorate of medicine and a doctorate of philosophy degree in biomedical engineering from Duke University. Following medical school, she matriculated to the resident staff at Memorial Sloan Kettering Cancer Center, receiving extensive oncologic training and research experience. She also completed a postdoctoral research fellowship at Johns Hopkins University in the Department of Radiology. Make A Gift. Dr. Kiess is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. Her top areas of expertise are Prostate Cancer, Laryngeal Cancer, Acinic Cell Carcinoma of Salivary Glands, Gastrostomy, and Adenoidectomy.

Dr. Daniel (Danny) Song is a Professor of Radiation Oncology, with joint appointments in Urology and Oncology. He serves as the Co-director of the Prostate Cancer Multidisciplinary Clinic at the Johns Hopkins Hospital and the Physician Advisor and Director of Faculty Affairs for the Department of Radiation Oncology and Molecular Radiation Sciences. His area of clinical expertise is in the management of genitourinary cancers, including cancers of the prostate, bladder and urinary tract, and testicular cancer. Dr. Song applies his expertise and clinical experience in the utilization of a variety of radiation modalities including external beam radiation, image-guided and intensity-modulated radiation, prostate brachytherapy (seed implants), and stereotactic body radiation therapy. Dr. Song's research interests include the development and refinement of new imaging methods to improve radiation targeting, as well as innovative means of reducing potential side effects of radiation treatment. His research is supported by federal and private research funding programs including two R01 awards from the National Cancer Institute, Department of Defense Prostate Cancer Clinical Trial Award, the American Cancer Society, and the Hopkins-BMS Immuno-Oncology Consortium. He is a reviewer and examiner for the American Board of Radiology, which administers the national board certification examination for radiation oncologists. He has served on the editorial boards of the International Journal of Radiation Oncology, Biology, Physics and The Prostate, and on the scientific review committees for the American Society for Radiation Oncology (ASTRO), American Brachytherapy Society, and the Dept of Defense Prostate Cancer Research Program. He currently serves on the Scientific Planning Committee for the American Brachytherapy Society annual meeting. He has co-authored consensus guidelines on stereotactic body radiation therapy (TG-101) and image-guided robotic brachytherapy (TG-192) produced by the American Association of Physics in Medicine. Dr. Song sees patients at the Johns Hopkins Hospital (downtown Baltimore) as well as Greenspring Station (Timonium) practices. Make A Gift. Dr. Song is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Muscle Invasive Bladder Cancer, and Non-Muscle Invasive Bladder Cancer.

Arthur Burnett is a Urologist in Baltimore, Maryland. Dr. Burnett is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Priapism, Erectile Dysfunction (ED), Peyronie Disease, Prostatectomy, and Penectomy.

William Dowling is a Urologist in Rosedale, Maryland. Dr. Dowling is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Familial Prostate Cancer, Prostate Cancer, Enlarged Prostate (BPH), UPJ Obstruction, and Ureteroscopy.

Brian Ramnaraign is an Oncologist in Baltimore, Maryland. Dr. Ramnaraign is rated as a Distinguished provider by MediFind in the treatment of Prostate Cancer. His top areas of expertise are Pancreatic Cancer, Colorectal Cancer, Familial Pancreatic Cancer, and Familial Colorectal Cancer.